The new signing comes as CSL Behring enters its 5th multiyear commitment to donate factor to the WFH Humanitarian Aid Program. As part of an existing agreement, CSL Behring will also provide 50 million IUs of coagulation factor replacement therapy over the next three years.
“As part of Our Promise to support those living with rare and serious diseases, CSL Behring has been providing life-saving, innovative solutions to people living with hematologic diseases for decades,” said Paul Perreault, Chief Executive Officer, and Managing Director, CSL. “As a long-standing partner of the WFH and a visionary contributor to the WFH Humanitarian Aid Program, we recognize that lack of access to treatment remains a major challenge and we are excited to see how this donation will address the significant unmet need that still exists in many developing countries.”
In addition to the product donation, the collaboration with CSL Behring and the WFH supports progress in improving the diagnosis and treatment of bleeding disorders through the WFH Path to Access to Care and Treatment (PACT) Program. CSL Behring will provide financial support for logistics costs and training programs designed to support existing unmet needs for people living with hemophilia who are undiagnosed, untreated, or undertreated.
“Over the years, CSL Behring has been a faithful partner of the WFH. This very significant donation will allow even more people with hemophilia benefit from treatment,” said Alain Baumann, WFH CEO. “Such donations will serve as a catalyst for improving access to care and treatment and take a step closer to our vision at the WFH, Treatment for All. We are grateful to CSL Behring to step up in their support of the WFH Humanitarian Aid Program.”
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org